AAAAAA
Results:
1-12
|
Results: 12
Authors:
Seregni, E
Ferrari, L
Martinetti, A
Bombardieri, E
Citation: E. Seregni et al., Diagnostic and prognostic tumor markers in the gastrointestinal tract, SEM SURG ON, 20(2), 2001, pp. 147-166
Authors:
Seregni, E
Martinetti, A
Ferrari, L
Bombardieri, E
Citation: E. Seregni et al., Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors, Q J NUCL M, 45(1), 2001, pp. 7-17
Authors:
Seregni, E
Ferrari, L
Bajetta, E
Martinetti, A
Bombardieri, E
Citation: E. Seregni et al., Clinical significance of blood chromogranin A measurement in neuroendocrine tumours, ANN ONCOL, 12, 2001, pp. S69-S72
Authors:
Bajetta, E
Del Vecchio, M
Vitali, M
Martinetti, A
Ferrari, L
Queirolo, P
Sertoli, MR
Cainelli, T
Cellerino, R
Cascinelli, N
Citation: E. Bajetta et al., A feasibility study using polychemotherapy (cisplatin plus vindesine plus dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma, TUMORI, 87(4), 2001, pp. 219-222
Authors:
Marinone, C
Martinetti, A
Mestriner, M
Seregni, E
Geuna, M
Ferrari, L
Strola, G
Bonardi, L
Fea, E
Bombardieri, E
Citation: C. Marinone et al., p53 evaluation in gastric mucosa of patients with chronic Helicobacter pylori infection, ANTICANC R, 21(2A), 2001, pp. 1115-1118
Authors:
Martinetti, A
Ferrari, L
Celio, L
Mariani, L
Miceli, R
Zilembo, N
Di Bartolomeo, M
Toffolatti, L
Pozzi, P
Seregni, E
Bombardieri, E
Bajetta, E
Citation: A. Martinetti et al., The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers, J STEROID B, 75(1), 2000, pp. 65-73
Authors:
Bajetta, E
Zilembo, N
Bichisao, E
Martinetti, A
Buzzoni, R
Pozzi, P
Bidoli, P
Ferrari, L
Celio, L
Citation: E. Bajetta et al., Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors, ANN ONCOL, 11(8), 2000, pp. 1017-1022
Authors:
Bajetta, E
Zilembo, N
Dowsett, M
Guillevin, L
Di Leo, A
Celio, L
Martinetti, A
Marchiano, A
Pozzi, P
Stani, S
Bichisao, E
Citation: E. Bajetta et al., Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients, EUR J CANC, 35(2), 1999, pp. 208-213
Authors:
Ferrari, L
Seregni, E
Bajetta, E
Martinetti, A
Bombardieri, E
Citation: L. Ferrari et al., The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours, ANTICANC R, 19(4C), 1999, pp. 3415-3427
Authors:
Celio, L
Martinetti, A
Ferrari, L
Buzzoni, R
Mariani, L
Miceli, R
Seregni, E
Procopio, G
Cassata, A
Bombardieri, E
Bajetta, E
Citation: L. Celio et al., Premenopausal breast cancer patients treated with a gonadotropin-releasinghormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study, ANTICANC R, 19(3B), 1999, pp. 2261-2268
Authors:
Molteni, SN
Seregni, E
Botti, C
Martinetti, A
Ferrari, L
Crippa, F
Bombardieri, E
Citation: Sn. Molteni et al., The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-medronate incorporation, ANTICANC R, 19(1A), 1999, pp. 255-259
Authors:
Bajetta, E
Ferrari, L
Martinetti, A
Celio, L
Procopio, G
Artale, S
Zilembo, N
Di Bartolomeo, M
Seregni, E
Bombardieri, E
Citation: E. Bajetta et al., Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors, CANCER, 86(5), 1999, pp. 858-865
Risultati:
1-12
|